Table 2. .
Baseline Ocular Characteristics of Study Participants (n = 5)
|
Patient |
Study Eye Assignment |
Visual Acuity (ETDRS letters, Snellen equivalent) |
Prior Treatments for DR |
OCT Thickness, Central Subfield (μm) |
|||
|
Study Eye |
Fellow Eye |
Study Eye |
Fellow Eye |
Study Eye |
Fellow Eye |
||
| 1 | OS | 60, 20/63 | 54, 20/80 | Focal laser | Focal laser, bevacizumab | 502 | 431 |
| 2 | OD | 72, 20/32 | 77, 20/32 | Focal laser, PRP | Focal laser, PRP | 527 | 495 |
| 3 | OD | 77, 20/32 | 85, 20/20 | Focal laser | None | 275 | 244 |
| 4 | OS | 57, 20/63 | 75, 20/32 | Focal laser, bevacizumab, PRP | Focal laser, bevacizumab | 425 | 280 |
| 5 | OS | 61, 20/63 | 80, 20/25 | Focal laser, bevacizumab, intravitreal triamcinolone | Focal laser | 470 | 312 |
| Mean | 65, 20/50 | 74, 20/32 | 440 | 352 | |||
| SD | 8.6 | 11.9 | 99.7 | 106.2 | |||
DR
diabetic retinopathy; ETDRS, Early Treatment of Diabetic Retinopathy Study; OCT, optical coherence tomography; OD, right eye; OS, left eye; PRP, pan-retinal photocoagulation; SD, standard deviation.